CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers
- Study to assess safety and immunogenicity of CVnCoV
- Study builds on observational epidemiological study
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced today that the first participant in a clinical Phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020. The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a two-dose schedule of 12 µg. The trial follows an epidemiological, non-interventional study conducted with healthcare workers from the University Hospital in Mainz.